Ongoing Phase 2b Clinical Trial and Upcoming Protocol Amendment (GlobeNewswire) - Nov 12, 2025 - "A protocol amendment will be submitted to the regulatory agencies with the intent to:
Expand the number and exposure range of dosing regimens studied to fully characterize the clinical profile, given the molecular features of IMG-007 and favorable tolerability profile seen to date; Characterize the role of loading doses in driving the magnitude of efficacy and time to onset of effect; Evaluate patient-friendly dosing intervals; Understand the role of short- and longer-term treatment; Optimize feasibility of successful study execution; Enrollment in the study is ongoing at North American sites and will continue; Topline data from the study is expected in 2027."
Clinical protocol • Enrollment status • P2b data • Atopic Dermatitis
|